0000000001002241

AUTHOR

Jean-charles Dagorn

showing 4 related works from this author

Cloning and Expression of the mRNA of Human Galectin-4, an S-type Lectin Down-Regulated in Colorectal Cancer

1997

We are interested in the characterization of genes whose expressions in the colon are modified during colorectal carcinogenesis. Our approach was to establish the phenotype of a colon tumor by partial sequencing of a large number of transcripts, then to select mRNAs of potential interest by differential screening with complex probes from normal or cancerous colon. In this paper, we report the cloning and sequencing of a mRNA strongly underexpressed in colorectal cancer. It corresponded to a protein comprising 323 amino acids, that appeared to be human galectin-4 on the basis of 76% and 79% amino acid identity to the rat and pig counterparts, respectively. Tissue distribution analysis showed…

Genetic MarkersDNA ComplementaryColorectal cancerGalectin 4Molecular Sequence DataDown-RegulationRectumBiologyBiochemistryLectinsBiomarkers TumorTumor Cells CulturedmedicineHumansAmino Acid SequenceRNA MessengerRNA NeoplasmCloning MolecularGeneCloningExpressed sequence tagMessenger RNABase SequenceSequence Homology Amino AcidDNA Neoplasmmedicine.diseaseMolecular biologyPhenotypedigestive system diseasesGene Expression Regulation NeoplasticHemagglutininsmedicine.anatomical_structureCell cultureColorectal NeoplasmsEuropean Journal of Biochemistry
researchProduct

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

2007

Pancreatic cancer is a disease with an extremely poor prognosis. Tumor protein 53-induced nuclear protein 1 ( TP53INP1 ) is a proapoptotic stress-induced p53 target gene. In this article, we show by immunohistochemical analysis that TP53INP1 expression is dramatically reduced in pancreatic ductal adenocarcinoma (PDAC) and this decrease occurs early during pancreatic cancer development. TP53INP1 reexpression in the pancreatic cancer-derived cell line MiaPaCa2 strongly reduced its capacity to form s.c., i.p., and intrapancreatic tumors in nude mice. This anti-tumoral capacity is, at least in part, due to the induction of caspase 3-mediated apoptosis. In addition, TP53INP1 −/− mouse embryonic…

Settore MED/06 - Oncologia MedicaTransplantation HeterologousGene ExpressionMice NudeMicePancreatic tumorPancreatic cancerCell Line TumormicroRNAGene expressionmedicineAnimalsHumansRNA NeoplasmNuclear proteinCaspaseHeat-Shock ProteinsMice KnockoutMultidisciplinarybiologyBase Sequenceapoptosis pancreatic cancer ponasterone A tumor suppressor micro RNANuclear ProteinsBiological Sciencesmedicine.diseaseTransplantationPancreatic NeoplasmsMicroRNAsCell Transformation NeoplasticApoptosisCancer researchbiology.proteinTumor Suppressor Protein p53Carrier ProteinsNeoplasm TransplantationCarcinoma Pancreatic DuctalProceedings of the National Academy of Sciences of the United States of America
researchProduct

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

2017

Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the a…

0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesmedicine.medical_treatment[SDV]Life Sciences [q-bio]Immunologybtn3apancreatic ductal adenocarcinomalcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicineImmunology and AllergyComputingMilieux_MISCELLANEOUSbusiness.industrycd277Aggressive cancerCancerPrognosis MarkerImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensbutyrophilin 3 adigestive system diseases3. Good health[SDV] Life Sciences [q-bio]030104 developmental biologyOncology030220 oncology & carcinogenesisimmunotherapybusinesslcsh:RC581-607Research Article
researchProduct

pap, reg I? andreg I? mRNAs are concomitantly up-regulated during human colorectal carcinogenesis

1999

We have established the phenotype of a colorectal tumor by partial sequencing of 2166 transcripts that were eventually arrayed on high-density filters. These filters were used for differential screening with mRNAs of colorectal cancer and normal adjacent mucosa to characterize genes whose expression is altered in colorectal carcinoma. Three genes encoding related proteins, PAP, reg Iα and reg Iβ, were over-expressed in cancer. Northern-blot analysis confirmed that their expression was very low in normal colonic epithelial cells, but elevated in 75% of tumors. Western blotting with specific antibodies to pap and reg Iα revealed in tumors a single band of the expected size (15–16 kDa), demons…

Cancer ResearchReporter genePathologymedicine.medical_specialtyCancerBiologymedicine.disease_causemedicine.diseaseMolecular biologyBlotOncologyGene expressionmedicineCarcinomaGene silencingImmunohistochemistryCarcinogenesisInternational Journal of Cancer
researchProduct